Home / Intelligence / Scientific Publications / Burden of Cremophor-related Paclitaxel Therapy on Patients with Ovarian Cancer: A Patient Focused Study from the United Kingdom, Germany, and Spain.
Cremophor EL (CrEL) is a solubilizer used in paclitaxel and is associated with side effects (i.e., hypersensitivity reactions, peripheral neuropathy). Current CrEL-containing therapies require long infusion times (2-4 hours) and pre-medication with steroids to manage these side-effects. However, the holistic burden of CrEL on patients is not well studied. This study aimed to characterize the burden associated with CrEL-paclitaxel treatment on patients with ovarian cancer, including clinical, safety, and quality of life (QoL) implications.
Authors
Diana Brixner, Anke-Peggy Holtorf, Ayesha Bhatia, Bhagyashree Oak, Sumudu Dehipawala, Clive Whitcher, Kate McKinley, Kyle Martin, Nandini Hadker
Journal
ASCO 2022
Related Intelligence
Blog
Learnings to Kick-Start 2025: Joint Clinical Assessments and Health Technology Assessments
One trend Trinity Life Sciences has observed and that was reinforced by stakeholders at ISPOR EU is the importance of evidence in healthcare decision-making. This trend was highlighted particularly in the context of joint clinical assessments (JCA) and health technology assessments (HTA). Trinity presented 11 posters at ISPOR EU, 6 of which focused on HTA and/or […]
Read More
Scientific Publications
ISPOR EU 2024 Research Posters
RWD8 Maximizing the Value of Real-World Data in HEOR – a Comparative Assessment of Claims and Emr Sources in Europe Authors: Diehl M, Saikumar S, Furrer DE, Kulkarni A, Patel N, Hadker N Abstract: OBJECTIVES: Heterogeneity in the European RWD landscape, both regionally and across vendors, requires fit-for-purpose dataset selection in HEOR studies. Visibility into […]
Read More
Blog
Rise with the Waves: UK – Now and Beyond – Four Policy Trends That May Shape Pharma’s Future
Executive Summary The global payer landscape is rapidly evolving and is expected to continuously impact manufacturers’ decisions about new launches, portfolio management, trial design and importantly, pricing and market access strategy. In the UK, several policy reforms have been introduced which are expected to improve patient access while balancing financial healthcare sustainability and overall market […]
Read More